Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841748 | 0.89 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL9262058 | 0.88 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL10893588 | 0.86 | CHRNB2 (0.60) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL2155811 | 0.85 | CYP2A6 (0.67) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL30938347 | 0.85 | CYP2A6 (0.67) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3044684 | 0.83 | CHRNB2 (0.70) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL5376053 | 0.81 | CHRNB2 (0.63) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL14085289 | 0.81 | CHRNB2 (0.69) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL14085349 | 0.81 | CYP2A6 (0.73) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL5032508 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| WO-2014144836-A2 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-0900200-B9 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-0900200-B1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997806-A1 | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders | Targacept, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-0801527-B1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| US-5616707-A | N-METHYL-4-PYRIDYL-3-BUT(ENE OR YNE)-1-AMINE | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| US-5604231-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS, DOPAMINERGIC AGENTS; SIDE EFFECT REDUCTION | TARGACEPT, INC. | 1997-02-18 | — | — | US | disclosed |
| US-5597919-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS RESULTING FROM NEUROTRANSMITTER DYSFUNCTION | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1997-01-28 | — | — | US | disclosed |
| WO-1996020929-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020599-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020600-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5428168-A | Substituted butyrolactol ether derivative | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-06-27 | — | — | US | disclosed |
| EP-0527817-A1 | GAMMA-BUTYROLACTOL ETHER DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991017157-A1 | GAMMA-BUTYROLACTOL ETHER DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | CHRNB2 2192/4885CHRNA4 1543/4885CYP2A6 537/4885 |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | CHRNB2 549/4885CHRNA4 543/4885CYP2A6 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.